Home › Companies › 10x Genomics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and 10x Genomics, Inc.’s Form 8-K, filed June 8, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 4, 2026: 5 items on 10x Genomics, Inc.’s Form 8-K, filed June 8, 2026: 2 approved · 3 passed (calculated).
Notable dissent: 1 director (13.4% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore 10x Genomics, Inc. in the interactive database Compare manager voting policies
These tallies are 10x Genomics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 8, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Serge Saxonov | 164,137,381 | 15,559,860 | 557,329 | -- | 18,560,948 | 91% | Passed (calculated) | — |
| Elect Director: Benjamin J. Hindson | 162,942,766 | 16,761,532 | 550,270 | -- | 18,560,950 | 91% | Passed (calculated) | — |
| Elect Director: John R. Stuelpnagel | 155,628,365 | 24,072,179 | 554,023 | -- | 18,560,951 | 87% | Passed (calculated) | — |
| 2. Ratification of Independent Registered Public Accounting Firm | 197,719,939 | 458,231 | 637,346 | -- | -- | 99.8% | Approved | — |
| 3. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers | 176,677,540 | 2,828,730 | 748,296 | -- | 18,560,952 | 98% | Approved | — |
Source: 10x Genomics, Inc., Form 8-K, filed with the SEC on June 8, 2026 — read the filing on EDGAR.
See voting trends for Industrials companies, 2025-2026: shareholder support by sector and by company size.
318 asset managers disclosed a vote on at least one 10x Genomics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expiring at the 2029 annual meeting of stockholders or until each such director's successor is duly elected and qualified or until each such director's earlier death, resignation, disqualification or removal: Benjamin J. Hindson
10x Genomics, Inc.’s own tally for this item (“Elect Director: Benjamin J. Hindson”): 162,942,766 for, 16,761,532 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 80 asset managers below reported 49,127,161 for, 3,211,324 against, 10,077 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 15,850,158 | 0 | 0 | 0 | For |
| Vanguard | 12,122,042 | 10,367 | 2 | 0 | For |
| ARK ETF Trust | 9,942,348 | 0 | 0 | 0 | For |
| BlackRock | 4,178,591 | 0 | 0 | 0 | For |
| Capital Group | 1,452,300 | 0 | 0 | 0 | For |
| Charles Schwab | 1,113,694 | 0 | 0 | 0 | For |
| T. Rowe Price | 31,337 | 661,961 | 0 | 0 | Against |
| Dimensional | 0 | 484,869 | 0 | 0 | Against |
| TIAA | 403,502 | 0 | 0 | 0 | For |
| Pacific Life | 382,118 | 0 | 0 | 0 | For |
| JPMorgan | 375,291 | 0 | 0 | 0 | For |
| Russell Investments | 367,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 361,947 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 348,357 | 0 | 0 | 0 | For |
| Equitable | 234,064 | 85,300 | 0 | 0 | Mixed |
| Nationwide | 33,983 | 259,317 | 0 | 0 | Mixed |
| American Century | 0 | 291,528 | 0 | 0 | Against |
| Columbia Threadneedle | 256,051 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 0 | 250,930 | 0 | 0 | Against |
| Principal Exchange-Traded Funds | 0 | 224,706 | 0 | 0 | Against |
| AMERICAN BEACON FUNDS | 183,165 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 179,252 | 0 | 0 | 0 | For |
| Nuveen | 176,714 | 0 | 0 | 0 | For |
| ARK Venture Fund | 146,869 | 0 | 0 | 0 | For |
| Lincoln Financial | 100,677 | 42,185 | 0 | 0 | Mixed |
Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expiring at the 2029 annual meeting of stockholders or until each such director's successor is duly elected and qualified or until each such director's earlier death, resignation, disqualification or removal: John R. Stuelpnagel
10x Genomics, Inc.’s own tally for this item (“Elect Director: John R. Stuelpnagel”): 155,628,365 for, 24,072,179 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 80 asset managers below reported 45,696,450 for, 6,642,035 against, 10,077 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 13,360,251 | 2,489,907 | 0 | 0 | Mixed |
| Vanguard | 12,115,926 | 16,483 | 2 | 0 | For |
| ARK ETF Trust | 9,942,348 | 0 | 0 | 0 | For |
| BlackRock | 4,178,591 | 0 | 0 | 0 | For |
| Capital Group | 1,452,300 | 0 | 0 | 0 | For |
| Charles Schwab | 1,113,694 | 0 | 0 | 0 | For |
| T. Rowe Price | 31,337 | 661,961 | 0 | 0 | Against |
| Dimensional | 0 | 484,869 | 0 | 0 | Against |
| TIAA | 0 | 403,502 | 0 | 0 | Against |
| Pacific Life | 382,118 | 0 | 0 | 0 | For |
| JPMorgan | 375,291 | 0 | 0 | 0 | For |
| Russell Investments | 367,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 361,947 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 348,357 | 0 | 0 | 0 | For |
| Equitable | 189,160 | 130,204 | 0 | 0 | Mixed |
| Nationwide | 33,983 | 259,317 | 0 | 0 | Mixed |
| American Century | 0 | 291,528 | 0 | 0 | Against |
| Columbia Threadneedle | 256,051 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 0 | 250,930 | 0 | 0 | Against |
| Principal Exchange-Traded Funds | 0 | 224,706 | 0 | 0 | Against |
| AMERICAN BEACON FUNDS | 183,165 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 179,252 | 0 | 0 | 0 | For |
| Nuveen | 0 | 176,714 | 0 | 0 | Against |
| ARK Venture Fund | 146,869 | 0 | 0 | 0 | For |
| Lincoln Financial | 26,177 | 116,685 | 0 | 0 | Mixed |
Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expiring at the 2029 annual meeting of stockholders or until each such director's successor is duly elected and qualified or until each such director's earlier death, resignation, disqualification or removal: Serge Saxonov
10x Genomics, Inc.’s own tally for this item (“Elect Director: Serge Saxonov”): 164,137,381 for, 15,559,860 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 80 asset managers below reported 49,924,039 for, 2,474,446 against, 10,077 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 15,850,158 | 0 | 0 | 0 | For |
| Vanguard | 12,122,045 | 10,364 | 2 | 0 | For |
| ARK ETF Trust | 9,942,348 | 0 | 0 | 0 | For |
| BlackRock | 4,178,591 | 0 | 0 | 0 | For |
| Capital Group | 1,452,300 | 0 | 0 | 0 | For |
| Charles Schwab | 1,113,694 | 0 | 0 | 0 | For |
| T. Rowe Price | 693,298 | 0 | 0 | 0 | For |
| Dimensional | 0 | 484,869 | 0 | 0 | Against |
| TIAA | 403,502 | 0 | 0 | 0 | For |
| Pacific Life | 382,118 | 0 | 0 | 0 | For |
| JPMorgan | 375,291 | 0 | 0 | 0 | For |
| Russell Investments | 367,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 361,947 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 348,357 | 0 | 0 | 0 | For |
| Equitable | 234,064 | 85,300 | 0 | 0 | Mixed |
| Nationwide | 33,983 | 259,317 | 0 | 0 | Mixed |
| American Century | 0 | 291,528 | 0 | 0 | Against |
| Columbia Threadneedle | 256,051 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 0 | 250,930 | 0 | 0 | Against |
| Principal Exchange-Traded Funds | 0 | 224,706 | 0 | 0 | Against |
| AMERICAN BEACON FUNDS | 183,165 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 179,252 | 0 | 0 | 0 | For |
| Nuveen | 176,714 | 0 | 0 | 0 | For |
| ARK Venture Fund | 146,869 | 0 | 0 | 0 | For |
| Lincoln Financial | 100,677 | 42,185 | 0 | 0 | Mixed |
Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).
Combines 14 wordings of this item as funds reported it.
98% Approved · of votes cast
Prior year: 83.6% for (June 3, 2025 meeting) ▲ 14.8 pts
Description as filed by funds: A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and
10x Genomics, Inc.’s own tally for this item (“3. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers”): 176,677,540 for, 2,828,730 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in more detail in the Company's definitive proxy state…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 15,850,158 | 0 | 0 | 0 | For |
| Vanguard | 12,132,405 | 3 | 3 | 0 | For |
| ARK ETF Trust | 9,942,348 | 0 | 0 | 0 | For |
| BlackRock | 4,178,591 | 0 | 0 | 0 | For |
| Capital Group | 0 | 1,452,300 | 0 | 0 | Against |
| Charles Schwab | 1,113,694 | 0 | 0 | 0 | For |
| T. Rowe Price | 693,298 | 0 | 0 | 0 | For |
| Dimensional | 484,869 | 0 | 0 | 0 | For |
| TIAA | 403,502 | 0 | 0 | 0 | For |
| Pacific Life | 382,118 | 0 | 0 | 0 | For |
| JPMorgan | 375,291 | 0 | 0 | 0 | For |
| Russell Investments | 367,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 361,947 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 348,357 | 0 | 0 | 0 | For |
| Equitable | 319,364 | 0 | 0 | 0 | For |
| Nationwide | 293,300 | 0 | 0 | 0 | For |
| American Century | 0 | 291,528 | 0 | 0 | Against |
| Columbia Threadneedle | 256,051 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 250,930 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 224,706 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 0 | 0 | 200,000 | 0 | Abstain |
| AMERICAN BEACON FUNDS | 183,165 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 179,252 | 0 | 0 | 0 | For |
| Nuveen | 176,714 | 0 | 0 | 0 | For |
| ARK Venture Fund | 146,869 | 0 | 0 | 0 | For |
Fund voting reports, all 81 managers: 50,515,091 for, 1,815,393 against, 210,078 abstained, 1 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 18,403,271 | 0 | 0 | 0 | For |
| Amova Asset Management Co., Ltd. | 5,090,395 | 0 | 0 | 0 | For |
| BlackRock | 3,233,355 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,904,416 | 0 | 0 | 0 | For |
| State Street | 2,232,168 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,541,227 | 0 | 0 | 0 | For |
| Capital Group | 0 | 1,452,300 | 0 | 0 | Against |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,148,579 | 0 | 0 | 0 | For |
| Charles Schwab | 1,115,763 | 0 | 0 | 0 | For |
| Blue Water Life Science Advisors, LP | 1,089,975 | 0 | 0 | 0 | For |
| Vanguard | 987,368 | 0 | 0 | 0 | For |
| AQR | 985,107 | 0 | 0 | 0 | For |
| Northern Trust | 811,911 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 807,928 | 0 | 0 | 0 | For |
| ARK Investment Management LLC | 743,596 | 0 | 0 | 0 | For |
| Goldman Sachs | 684,901 | 0 | 0 | 0 | For |
| Nuveen | 625,867 | 0 | 0 | 0 | For |
| Federated Hermes | 593,263 | 0 | 0 | 0 | For |
| Freshford Capital Management, LLC | 587,149 | 0 | 0 | 0 | For |
| STATE OF MICHIGAN RETIREMENT SYSTEM | 572,925 | 0 | 0 | 0 | For |
| Janus Henderson | 512,028 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 505,902 | 0 | 0 | 0 | For |
| Sands Capital Alternatives, LLC | 481,770 | 0 | 0 | 0 | For |
| BOSTON MANAGEMENT & RESEARCH | 467,079 | 0 | 0 | 0 | For |
| Russell Investments | 440,843 | 0 | 0 | 0 | For |
Institutional-manager reports, all 263 managers: 52,853,812 for, 2,338,954 against, 530,146 abstained, 735 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Prior year: 99.9% for (June 3, 2025 meeting) ▼ 0.1 pts
Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;
10x Genomics, Inc.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 197,719,939 for, 458,231 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 80 asset managers below reported 52,338,484 for, 10,077 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 15,850,158 | 0 | 0 | 0 | For |
| Vanguard | 12,132,408 | 0 | 2 | 0 | For |
| ARK ETF Trust | 9,942,348 | 0 | 0 | 0 | For |
| BlackRock | 4,178,591 | 0 | 0 | 0 | For |
| Capital Group | 1,452,300 | 0 | 0 | 0 | For |
| Charles Schwab | 1,113,694 | 0 | 0 | 0 | For |
| T. Rowe Price | 693,298 | 0 | 0 | 0 | For |
| Dimensional | 484,869 | 0 | 0 | 0 | For |
| TIAA | 403,502 | 0 | 0 | 0 | For |
| Pacific Life | 382,118 | 0 | 0 | 0 | For |
| JPMorgan | 375,291 | 0 | 0 | 0 | For |
| Russell Investments | 367,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 361,947 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 348,357 | 0 | 0 | 0 | For |
| Equitable | 319,364 | 0 | 0 | 0 | For |
| Nationwide | 293,300 | 0 | 0 | 0 | For |
| American Century | 291,528 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 256,051 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 250,930 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 224,706 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 183,165 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 179,252 | 0 | 0 | 0 | For |
| Nuveen | 176,714 | 0 | 0 | 0 | For |
| ARK Venture Fund | 146,869 | 0 | 0 | 0 | For |
| Lincoln Financial | 142,862 | 0 | 0 | 0 | For |
Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 127,691,329 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 12.41% |
| 2 | Vanguard | 9.50% |
| 3 | ARK ETF Trust | 7.79% |
| 4 | BlackRock | 3.27% |
| 5 | Capital Group | 1.14% |
| 6 | Charles Schwab | 0.87% |
| 7 | T. Rowe Price | 0.54% |
| 8 | Dimensional | 0.38% |
| 9 | TIAA | 0.32% |
| 10 | Pacific Life | 0.30% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.41% |
| 2 | Amova Asset Management Co., Ltd. | 3.99% |
| 3 | BlackRock | 2.53% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 2.27% |
| 5 | State Street | 1.75% |
| 6 | T. Rowe Price | 1.21% |
| 7 | Capital Group | 1.14% |
| 8 | JACOBS LEVY EQUITY MANAGEMENT, INC | 0.90% |
| 9 | Charles Schwab | 0.87% |
| 10 | Blue Water Life Science Advisors, LP | 0.85% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 17,740,972 | 13.89% | Form 13F, quarter ended March 31, 2026 |
| T. Rowe Price Associates, Inc. | 14,044,020 | 11.00% | Schedule 13G, filed September 8, 2026 |
| Vanguard Group | 13,017,914 | 10.19% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 10,079,913 | 7.89% | Form 13F, quarter ended March 31, 2026 |
| ARK Investment Management LLC | 10,003,058 | 7.83% | Schedule 13G, filed August 14, 2026 |
| Vanguard Portfolio Management | 6,981,683 | 5.47% | Schedule 13G, filed April 28, 2026 |
| Goldman Sachs | 4,109,100 | 3.22% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 3,196,893 | 2.50% | Form 13F, quarter ended March 31, 2026 |
| State Street | 2,588,795 | 2.03% | Form 13F, quarter ended March 31, 2026 |
| Dimensional Fund Advisors | 2,042,950 | 1.60% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 127,691,329 shares outstanding, as reported by 10x Genomics, Inc. on its Form 10-K dated December 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At 10x Genomics, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 318 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,804 separate fund positions. On the most widely held item on that ballot — A vote to approve, on a non-binding, advisory basis, the compensation of our named executive… — 10x Genomics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: 10x Genomics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 8, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 10x Genomics, Inc.’s 10-K dated December 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
10x Genomics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “10x Genomics (TXG) 2026 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/10x-genomics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.